‼️ Early or late is not a mindset; it’s a measurement.
When breast cancer is found early (localized), the 5-year survival rate is >99%. Yet we still funnel women into an invasive, anxious, and expensive pathway: ~1.59M breast biopsies a year in the U.S., 65–75% of them benign. That’s ~$3.07B in biopsy spend alone at $1,938 average cost, plus delays that push treatment later.
👉 PONS fixes the upstream failure.
Our device-agnostic AI upgrades standard ultrasound, sharper tissue contrast, noise suppression, and digital contrast (no injections). Clinicians get first-pass clarity and an AI risk report that helps triage who truly needs a biopsy now, and who doesn’t. Fewer unnecessary procedures. Faster answers for the women who do need care.
That’s not just efficiency, it’s survival.
Cut avoidable biopsies by 10% → save >$300M annually and reallocate time to earlier, lifesaving interventions.
Minutes to see → days to act → lives extended.
Join pilots where “early” means >99%.
Investment
Collaboration
Partnership